| . | . | Negative expression . | Positive expression . |
|---|---|---|---|
| IGFR1, n = 35 | 27 (77.1%) | 8 (22.9%) | |
| PFS | Events, n | 8 (29.6%) | 4 (50.0%) |
| Estimated survival (SD) | 49.5% (16.4%) | 0% | |
| Mean (SD), months | 10.0 (0.6) | 10.2 (0.8) | |
| Median | 11.5 | 10.7 | |
| p value (log‐rank test) | p = .635 | ||
| OS | Events, n | 8 (29.6%) | 0 (0%) |
| Estimated survival (SD) | 49.2% (13.8%) | 100% | |
| p value (log‐rank test) | p = .105 | ||
| pmTOR (n = 38) | 33 (86.8%) | 5 (13.2%) | |
| PFS | Events, n | 10 (30.3%) | 2 (40.0%) |
| Estimated survival (SD) | 50% (25.0%) | 0% | |
| Mean (SD), months | 10.0 (0.5) | 10.9 (0.6) | |
| Median | NR | 10.7 | |
| p value (log‐rank test) | p = .947 | ||
| OS | Events, n | 8 | 1 |
| Estimated survival (SD) | 48.9% (14.1%) | 80.0% (17.9%) | |
| Mean (SD), months | 33.3 (3.1) | 33.7 (5.5) | |
| p value (log‐rank test) | p = .560 | ||
| pS6 (n = 34) | 32 (94.1%) | 2 (5.9%) | |
| PFS | Events, n | 10 (31.3%) | 1 (50.0%) |
| Estimated survival (SD) | 51.2% (13.9%) | 0% | |
| Mean (SD), months | 10.5 (0.4) | 9.0 (0) | |
| Median | NR | 9.0 | |
| p value (log‐rank test) | p = .165 | ||
| OS | Events, n | 7 (21.9%) | 1 (50.0%) |
| Estimated survival (SD) | 61.6% (12.3%) | 0% | |
| Mean (SD), months | 35.6 (2.9) | 9.1 (0) | |
| p value (log‐rank test) | p = .005 | ||
| . | . | Negative expression . | Positive expression . |
|---|---|---|---|
| IGFR1, n = 35 | 27 (77.1%) | 8 (22.9%) | |
| PFS | Events, n | 8 (29.6%) | 4 (50.0%) |
| Estimated survival (SD) | 49.5% (16.4%) | 0% | |
| Mean (SD), months | 10.0 (0.6) | 10.2 (0.8) | |
| Median | 11.5 | 10.7 | |
| p value (log‐rank test) | p = .635 | ||
| OS | Events, n | 8 (29.6%) | 0 (0%) |
| Estimated survival (SD) | 49.2% (13.8%) | 100% | |
| p value (log‐rank test) | p = .105 | ||
| pmTOR (n = 38) | 33 (86.8%) | 5 (13.2%) | |
| PFS | Events, n | 10 (30.3%) | 2 (40.0%) |
| Estimated survival (SD) | 50% (25.0%) | 0% | |
| Mean (SD), months | 10.0 (0.5) | 10.9 (0.6) | |
| Median | NR | 10.7 | |
| p value (log‐rank test) | p = .947 | ||
| OS | Events, n | 8 | 1 |
| Estimated survival (SD) | 48.9% (14.1%) | 80.0% (17.9%) | |
| Mean (SD), months | 33.3 (3.1) | 33.7 (5.5) | |
| p value (log‐rank test) | p = .560 | ||
| pS6 (n = 34) | 32 (94.1%) | 2 (5.9%) | |
| PFS | Events, n | 10 (31.3%) | 1 (50.0%) |
| Estimated survival (SD) | 51.2% (13.9%) | 0% | |
| Mean (SD), months | 10.5 (0.4) | 9.0 (0) | |
| Median | NR | 9.0 | |
| p value (log‐rank test) | p = .165 | ||
| OS | Events, n | 7 (21.9%) | 1 (50.0%) |
| Estimated survival (SD) | 61.6% (12.3%) | 0% | |
| Mean (SD), months | 35.6 (2.9) | 9.1 (0) | |
| p value (log‐rank test) | p = .005 | ||
The median OS was not reached in any of the patient populations.
Abbreviations: IGFR1, insulin‐like growth factor 1 receptor; NR, not reached; OS, overall survival; PFS, progression‐free survival; pmTOR, phosphorylated mammalian target of rapamycin; pS6, phosphoS6; SD, standard deviation.
| . | . | Negative expression . | Positive expression . |
|---|---|---|---|
| IGFR1, n = 35 | 27 (77.1%) | 8 (22.9%) | |
| PFS | Events, n | 8 (29.6%) | 4 (50.0%) |
| Estimated survival (SD) | 49.5% (16.4%) | 0% | |
| Mean (SD), months | 10.0 (0.6) | 10.2 (0.8) | |
| Median | 11.5 | 10.7 | |
| p value (log‐rank test) | p = .635 | ||
| OS | Events, n | 8 (29.6%) | 0 (0%) |
| Estimated survival (SD) | 49.2% (13.8%) | 100% | |
| p value (log‐rank test) | p = .105 | ||
| pmTOR (n = 38) | 33 (86.8%) | 5 (13.2%) | |
| PFS | Events, n | 10 (30.3%) | 2 (40.0%) |
| Estimated survival (SD) | 50% (25.0%) | 0% | |
| Mean (SD), months | 10.0 (0.5) | 10.9 (0.6) | |
| Median | NR | 10.7 | |
| p value (log‐rank test) | p = .947 | ||
| OS | Events, n | 8 | 1 |
| Estimated survival (SD) | 48.9% (14.1%) | 80.0% (17.9%) | |
| Mean (SD), months | 33.3 (3.1) | 33.7 (5.5) | |
| p value (log‐rank test) | p = .560 | ||
| pS6 (n = 34) | 32 (94.1%) | 2 (5.9%) | |
| PFS | Events, n | 10 (31.3%) | 1 (50.0%) |
| Estimated survival (SD) | 51.2% (13.9%) | 0% | |
| Mean (SD), months | 10.5 (0.4) | 9.0 (0) | |
| Median | NR | 9.0 | |
| p value (log‐rank test) | p = .165 | ||
| OS | Events, n | 7 (21.9%) | 1 (50.0%) |
| Estimated survival (SD) | 61.6% (12.3%) | 0% | |
| Mean (SD), months | 35.6 (2.9) | 9.1 (0) | |
| p value (log‐rank test) | p = .005 | ||
| . | . | Negative expression . | Positive expression . |
|---|---|---|---|
| IGFR1, n = 35 | 27 (77.1%) | 8 (22.9%) | |
| PFS | Events, n | 8 (29.6%) | 4 (50.0%) |
| Estimated survival (SD) | 49.5% (16.4%) | 0% | |
| Mean (SD), months | 10.0 (0.6) | 10.2 (0.8) | |
| Median | 11.5 | 10.7 | |
| p value (log‐rank test) | p = .635 | ||
| OS | Events, n | 8 (29.6%) | 0 (0%) |
| Estimated survival (SD) | 49.2% (13.8%) | 100% | |
| p value (log‐rank test) | p = .105 | ||
| pmTOR (n = 38) | 33 (86.8%) | 5 (13.2%) | |
| PFS | Events, n | 10 (30.3%) | 2 (40.0%) |
| Estimated survival (SD) | 50% (25.0%) | 0% | |
| Mean (SD), months | 10.0 (0.5) | 10.9 (0.6) | |
| Median | NR | 10.7 | |
| p value (log‐rank test) | p = .947 | ||
| OS | Events, n | 8 | 1 |
| Estimated survival (SD) | 48.9% (14.1%) | 80.0% (17.9%) | |
| Mean (SD), months | 33.3 (3.1) | 33.7 (5.5) | |
| p value (log‐rank test) | p = .560 | ||
| pS6 (n = 34) | 32 (94.1%) | 2 (5.9%) | |
| PFS | Events, n | 10 (31.3%) | 1 (50.0%) |
| Estimated survival (SD) | 51.2% (13.9%) | 0% | |
| Mean (SD), months | 10.5 (0.4) | 9.0 (0) | |
| Median | NR | 9.0 | |
| p value (log‐rank test) | p = .165 | ||
| OS | Events, n | 7 (21.9%) | 1 (50.0%) |
| Estimated survival (SD) | 61.6% (12.3%) | 0% | |
| Mean (SD), months | 35.6 (2.9) | 9.1 (0) | |
| p value (log‐rank test) | p = .005 | ||
The median OS was not reached in any of the patient populations.
Abbreviations: IGFR1, insulin‐like growth factor 1 receptor; NR, not reached; OS, overall survival; PFS, progression‐free survival; pmTOR, phosphorylated mammalian target of rapamycin; pS6, phosphoS6; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
